ANALYSIS OF INFLUENCE OF LIVER FIBROSIS ON EFFICACY AND SAFETY OF ANTI-HELICOBACTER THERAPY


Andreev D.N., Maev I.V., Dicheva D.T., Kucheryavy Yu.A., Partsvania-Vinogradova E.V.

SBEI HPE "Moscow State Medical Stomatological University n.a. A.I. Evdokimov" of RMPH, Moscow
The article presents the results of a prospective clinical study aimed to the evaluation of the efficacy and safety of anti-Helicobacter therapy (AHT) in patients with concomitant chronic hepatitis C, depending on the stage of liver fibrosis. The data obtained allow to conclude that the effectiveness of AHT is not significantly dependent on the stage of liver fibrosis, but the presence of fibrosis significantly determines the risk of side effects on the background of the AHT. The group of highest risk includes patients with liver cirrhosis.

Literature


  1. Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М., 2015.
  2. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Тер. архив. 2014;3:94–9.
  3. Malfertheiner P., Megraud F., O’Morain C., Atherton J., Axon A.T., Bazzoli F., Gensini G.F., Gisbert J.P., Graham D.Y., Rokkas T., El-Omar E.M., Kuipers E.J.;. Management of Helicobacter pylori infection – Maastricht IV. Florence Consensus Report Gut. 2012; 61:646–64.
  4. El-Masry S., El-Shahat M., Badra G., Aboel-Nour M.F., Lotfy M. Helicobacter pylori and Hepatitis C Virus Coinfection in Egyptian Patients. J. Glob. Infect. Dis. 2010;2(1):4–9.
  5. Furusyo N., Walaa A.H., Eiraku K., Toyoda K., Ogawa E., Ikezaki H., Ihara T., Hayashi T., Kainuma M., Murata M., Hayashi J. Treatment for Eradication of Helicobacter pylori Infection among Chronic Hepatitis C Patients. Gut. Liver. 2011;5(4):447–53.
  6. Ponzetto A., Pellicano R., Redaelli A., Rizzetto M., Roffi L. Helicobacter pylori infection in patients with Hepatitis C Virus positive chronic liver diseases. New Microbiol. 2003;26(4):321–28.
  7. Wedemeyer H. Hepatitis C. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. edited by Mark Feldman, Lawrence S. Friedman, Laurence J. Brandt. 10th ed. 2015.
  8. Murray M. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clin. Pharmacokinet. 1992;23(2):132–46.
  9. Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin. Pharmacokinet. 1999;37(5):399–31.
  10. 14C
  11. Halilovic J., Heintz B.H. Antibiotic dosing in cirrhosis. Am. J. Health. Syst. Pharm. 2014;71(19):1621–34.
  12. de Boer W.A., Thys J.C., Borody T.J., Graham D.Y., O’Morain C., Tytgat G.N. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur. J. Gastroenterol. Hepatol. 1996;8(7):641–43.


About the Autors


D.N. Andreev – Teaching Assistant at the Department of Propedeutics of Internal Diseases and Gastroenterology SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH, Moscow; e-mail: dna-mit8@mail.ru
I.V. Maev – Doctor of Medical Sciences, Prof., Corr. Member of RAS, Honored Doctor of the Russian Federation, Honored Scientist of the Russian Federation, Vice-Rector for Academic Affairs, Head of the Department of Propedeutics of Internal Diseases and Gastroenterology SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH, Moscow
D.T. Dicheva – PhD in Medical Scineces, Associate Professor at the Department of Propedeutics of Internal Diseases and Gastroenterology SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH, Moscow
Yu.A. Kucheryavy - PhD in Medical Scineces, Associate Professor at the Department of Propedeutics of Internal Diseases and Gastroenterology SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH, Moscow
E.V. Partsvania-Vinogradova - Postgraduate Student at the Department of Propedeutics of Internal Diseases and Gastroenterology SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH, Moscow


Similar Articles


Бионика Медиа